HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
Hangzhou Highlightll Pharmaceutical Co., Ltd
156 participants
May 26, 2026
INTERVENTIONAL
Conditions
Summary
This study is a randomized, double-blind, placebo-controlled, multicenter Phase Ib/II clinical study designed to evaluate the efficacy, safety, and PK characteristics of HL-300 ointment with different concentration regimens for mild-to-moderate AD.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Group A receives the investigational product at a concentration of 0.25%, BID,4 weeks.
BID, day 7.
Group B receives the investigational product at a concentration of 0.5%, BID,4 weeks.
Group A receives the investigational product at a concentration of 1.0%, BID,4 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07629778